Results 191 to 200 of about 10,510,072 (298)
Community pharmacy transformation under universal health coverage: Implementation barriers, cultural determinants, and cross-national lessons from Japan's ongoing transition - A narrative review. [PDF]
Urakawa R +3 more
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Call for papers: strengthening primary care through integrated clinical pharmacy services-models, outcomes and implementation. [PDF]
Nazar Z, Sahm L, Kallis T.
europepmc +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Questioning the cost of convenience: a mixed methods study of the impact of a telehealth service delivery on pharmacists' work. [PDF]
Carland JE +5 more
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Building on the 2025 national academies pharmacy workshop: ensuring access to community pharmacist care. [PDF]
Bacci JL +4 more
europepmc +1 more source
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk +5 more
wiley +1 more source
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source

